

DAFTAR PUSTAKA

- Aguiar, F., Fernandes, G., Queiroga, H., Machado, J. C., Cirnes, L., *et al.*, 2018. Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. *Arch Bronconeumol.* 54(1):10–17.
- American Lung Association. 2010. State of Lung Disease in Diverse Communities. Available from: URL: <http://action.lung.org/site/DocServer/state-of-lung-disease-in-diverse-communities-2010.pdf> pada tanggal 8 Mei 2019.
- Amin, Z., 2014. Kanker Paru. Dalam: Sudoyo, A.W., Setryohadi, B., Alwi, I., Simadibrata, M.K., Setiati, S. *Ilmu Penyakit Dalam Ed 6*, pp: 2998-3007. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia.
- Aschengrau, A., Seage, G. R., 2008. *Essentials of Epidemiology in Public Health 2nd edition*. Massachusetts: Jones and Bartlett Publishers.
- Bethune, G., Bethune, D., Ridgway, N., Xu, Z. 2010. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. *J Thorac Dis*; 2: 48-51.
- Beypinar, I., Demir, H., Araz, M., Uysal, M.. 2019. The relationship between EGFR mutation and metastasis pattern in lung adenocarcinoma. *J Oncol Sci* 5:65-69.
- Bi, J., Han, G., Wei, X., Pi, G., Zhang, Y., Li, Y., *et al.* 2018. The features and prognostic impact of extracranial metastases in patients with epidermal growth factor receptor-mutant lung adenocarcinoma. *J Can Res Ther* 14:799-806.
- Brambilla, E., Gazdar, A. 2009. Pathogenesis of lung cancer signaling pathways: roadmap for therapies. *Eur Respir J.* Jun; 33(6): 1485–1497.
- Cabanero, M., Sangha, R., Sheffield, B.S., Sukhai, M., Pakkal, M., Kamel-Reid, S., *et al.* 2017. Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. *Curr Oncol.* Apr;24(2):111-119.
- Chang, W.Y., Wu, Y.L., Su, P.L., Yang, S.C., Lin, C.C., Su, W.C. 2018. The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. *PLoS ONE* 13(2): e0192161.

- Cheema, P.K, Burkes, R.L. 2013. Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer. *Curr Oncol.* Apr; 20(2): e150–e160.
- Chen, Yen-Fu, Hsieh, Min-Shu, Wu, Shang-Gin, Chang, Yih-Leong, Shih, Jin-Yuan, Liu, Yi-Nan, *et al.* 2014. Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations. *J Thorac Oncol* 9: 1171–1179.
- Cheng, L., Alexander, R.E., Maclennan, G.T., Cummings, O.W., Montironi, R., Lopez-Beltran, A. 2012. Molecular pathology of lung cancer: key to personalized medicine. *Modern Pathology* 25:347–369.
- Chi, A., Remick, S., Tse, W. 2013. EGFR inhibition in non-small cell lung cancer: current evidence and future directions. *Biomarker Research* 1:2.
- Chia, P.L., Mitchell, P., Dobrovic, A, John, T. 2014. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. *Clinical Epidemiology*:6 423–432.
- Comber, H., Cronin, D.P., Deady, S., Lorcaín, P.O., Riordan, P. 2005. Delays in treatment in the cancer services: impact on cancer stage and survival. *Ir Med J.*;98(8):238-239.
- Douillard, J.Y., Shepherd, F.A., Hirsh, V., Harris, P.L., Okimoto, R.A., Brannigan, B.W., *et al.* 2005. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. *J. Clin. Oncol.* 23, 8081–8092.
- Driscoll, T., Nelson, D.I., Steenland, K., Leigh, J., Concha-Barrientos, M., Fingerhut, M., *et al.* 2005. The global burden of disease due to occupational carcinogens. *Am J Ind Med.* Dec;48(6):419-31.
- Du, W.W., Fang, L., Yang, W., Sheng, W., Zhang, Y., Seth, A, *et al.* 2012. The role of versican G3 domain in regulating breast cancer cell motility including effects on osteoblast cell growth and differentiation in vitro – Evaluation towards understanding breast cancer cell bone metastasis. *BMC Cancer* 12:341.
- Dupont, W.D., Plummer, W.D. 1998. Power and Sample Size Calculations for Studies Involving Linear Regression. *Controlled Clinical Trials*; 19:589-601.

- Ettinger, D.S., Wood, D.E., Aisner, D.L., Akerley, W., Bauman, J., Chang, J.Y., *et al.* 2018. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer. Available at: URL: http://oncolife.com.ua/doc/nccn/Non-Small_Cell_Lung_Cancer
- Fang, S., Wang, Z. 2014. EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. *Drug Design, Development and Therapy*:8 1595–1611.
- Fang, S., Wang, Z., Guo, J., Liu, J., Li, C., Liu, L. 2014. Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer. *OncoTargets and Therapy*:7 1185–1193.
- Fawziah, A., Sari, N.K., Uyainah, A., Soetandyo, N., Dewiasty, E. 2015. Kesintasan Satu Tahun Penderita Karsinoma Paru Bukan Sel Kecil Stadium IIIB/ IV Usia Lanjut yang Menjalani Kemoterapi Dibandingkan dengan Non-Kemoterapi. Diakses melalui <http://lib.ui.ac.id/file?file=digital/2016-3/20405312-SP-Ana%20Fawziah.pdf> pada tanggal 8 Mei 2019.
- Fenchel, K., Sellmann, L., Dempke, W.C.M. 2016. Overall survival in non-small cell lung cancer—what is clinically meaningful? *Transl Lung Cancer Res.* Feb; 5(1): 115–119.
- Friis, R.H., Sellers, T.A. 2014. *Epidemiology for Public Health Practice 5th edition*. Massachusetts: Jones and Bartlett Publishers.
- Howlader, N., Noone, A.M., Krapcho, M., Garshell, J., Miller, D., Altekruse, S.F., *et al.* 2014. SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/archive/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
- Hsiao, S.H., Chou, Y.T., Lin, S.E., Hsu, R.C., Chung, C.L., Kao, Y.R., *et al.* 2017. Brain metastases in patients with non-small cell lung cancer: the role of mutated-EGFRs with an exon 19 deletion or L858R point mutation in cancer cell dissemination. *Oncotarget*, Vol. 8, (No. 32), pp: 53405-53418.
- Hsu, F., Caluwe, A.D., Anderson, D., Nichol, A., Toriumi, T., Ho, C. 2017. Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations. *Curr Oncol.* Aug;24(4):228-233.
- Hwang, I.K., Paik, S.S., Lee, S.H.. 2019. Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma. *Cancer Res Treat.* 51(1):158-168.

- International Agency for Research on Cancer (IARC)/ WHO. 2012. GLOBOCAN 2012: Estimated cancer incidence, mortality, and prevalence worldwide in 2012. Diakses melalui http://globocan.iarc.fr/Pages/fact_sheets_population pada tanggal 30 Januari 2019.
- Isaka, T., Nakayama, H., Ito, H., Yokose, T., Yamada, K., Masuda, M., *et al.* 2018. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery. *BMC Cancer* 18:959.
- Isla, D., Majem, M., Vinolas, N., Artal, A., Blasco, A., Felip, E., *et al.* 2017. A consensus statement on the gender perspective in lung cancer. *Clin Transl Oncol* 19:527–535.
- Islam, K.M., Jiang, X., Anggondowati, T., Lin, G., Ganti, A.K. 2015. Comorbidity and Survival in Lung Cancer Patients. *Cancer Epidemiol Biomarkers Prev.* Jul;24(7):1079-85.
- Izquierdo, J.L., Resano, P., El-Hachem, A., Graziani, D., Almonacid, C., Sanchez, I.M. 2014. Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors. *Int J Chron Obstruct Pulmon Dis.*9:1053–1058.
- Kim, S.Y., Myung, J.K., Kim, Hye-Ryoun, Na, I.I., Koh, J.S., Baek, H.J., *et al.* 2019. Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma. *Tuberc Respir Dis* 82:62-70.
- Komite Penanggulangan Kanker Nasional. 2016. *Pedoman Nasional Pelayanan Kedokteran Kanker Paru*. Kementerian Kesehatan Republik Indonesia. Jakarta.
- Kuo, C. H., Lo, C. Y., Chung, F. T., Lee, K. Y., Lin, S. M., Wang, C. H., *et al.* 2012. Concomitant active tuberculosis prolongs survival in non-small cell lung cancer: a study in a tuberculosis-endemic country. *PloS one*, 7(3), e33226.
- Lee, C.K., Brown, C., Gralla, R.J., Hirsh, V., Thongprasert, S., Tsai, Chun-Ming, Tan, E.H., *et al.* 2013. Impact of eGFR inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. *J Natl Cancer Inst*; 105:595–605
- Lee, S.J., Lee, J., Park, Y.S., Lee, Chang-Hoon, Lee, Sang-Min, Yim, Jae-Joon, *et al.* 2004. Impact of Chronic Obstructive Pulmonary Disease on the Mortality of Patients with Non–Small-Cell Lung Cancer. *J Thorac Oncol.*9: 812–817.

- Lim, J.U., Yeo, C.D., Rhee, C.K., Kang, H.S., Park, C.K., Kim, J.S., *et al.* 2018. Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients. *Int J Chron Obstruct Pulmon Dis.* 13:2139–2146.
- Lim, J.U., Yeo, C.D., Rhee, C.K., Kim, Y.H., Park, C.K., Kim, J.S., *et al.* 2019. Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients. *International Journal of Chronic Obstructive Pulmonary Disease* 14: 929–938 .
- Lopes, G., Wu, Yi-Long, Kudaba, I., Kowalski, D., Cho, B.C., Castro, G., *et al.* Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) $\geq 1\%$: Open-label, phase 3 KEYNOTE-042 study. *J Clin Oncol* 36(18 Suppl): LBA4.
- Lue, H.W., Yang, X., Wang, R., Qian, W., Xu, R.Z., Lyles, R., *et al.* 2011. LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling. *PLoS One* 6:e27720.
- Luo, Yung-Hung, Wu, Chieh-Hung, Wu, Wen-Shuo, Huang, Chu-Yun, Su, Wei-Juin, Tsai, Chun-Ming, *et al.* 2012. Association between Tumor Epidermal Growth Factor Receptor Mutation and Pulmonary Tuberculosis in Patients with Adenocarcinoma of the Lungs. *J Thorac Oncol.* 7: 299–305.
- Melosky, B. 2014. Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. *Frontiers in oncology*, 4, 256.
- Midha, A., Dearden, S., McCormack, R. 2015. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). *Am J Cancer Res* 5(9):2892-2911.
- Mok, T.S., Wu, Y.L., Thonggpraset, S. 2009. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med.* 361: 947–57.
- Myrdal, G., Lambe, M., Hillerdal, G., Lamberg, K., Agustsson, Th., Stahle, E. 2004. Effect of delays on prognosis in patients with non-small cell lung cancer. *Thorax*; 59:45–49.
- Nakahama, K., Tamiya, A., Taniguchi, Y., Naoki, Y., Kanazu, M., Atagi, S. 2017. Comparing Gefitinib and Erlotinib With Regard To Brain Metastases

Recurrence in EGFR-Mutant Non-Small Cell Lung Cancer Patients. *J ClinExpOncol* 6:4.

- Neal, R. D., Allgar, V. L., Ali, N., Leese, B., Heywood, P., Proctor, G., & Evans, J. 2007. Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes. *The British journal of general practice : the journal of the Royal College of General Practitioners*, 57(536), 212–219.
- Olsson, J.K., Schultz, E.M., Gould, M.K. 2009. Timeliness of care in patients with lung cancer: a systematic review. *Thorax*; 64:749–756.
- Omote, N., Hashimoto, N., Morise, M., Sakamoto, S., Miyazaki, S., Ando, A., *et al.* 2017. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy. *Int J Chron Obstruct Pulmon Dis*.12:3541–3547.
- Parsons, A., Daley, A., Begh, R., Aveyard, P. 2010. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. *BMJ*. Jan 21;340:b5569.
- Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E.F., Faivre-Finn, C., *et al.* 2018. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. Oct 1;29(Supplement_4):iv192-iv237.
- Radzikowska, E., Głaz, P., Roszkowski, K. 2002. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. *Ann Oncol*. Jul;13(7):1087-93.
- Ramnath, N., Dilling, T.J., Harris, L.J., Ki, A.W., Michaud, G.C., Balekian, A.A., *et al.* 2013. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. May;143(5 Suppl):e314S-40S.
- Reckamp, K.L. 2016. *Lung Cancer Treatment and Research*. Switzerland: Springer International Publishing.
- Rivera, P.M., Mehta, A.C., Wahidi, M.M. 2014. Diagnosis and management of lung cancer, 3rd ed: American college of physicians evidence-based clinical practice guidelines. *Chest*; 143(5): 142 – 165.
- Shieh, S.H., Probst, J.C., Sung, F.C., Tsai, W.C., Li, Y.S., Chen, C.Y. 2012. Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes. *BMC Cancer*. May 11;12:174.

- Shim, H. S., Choi, Y. L., Kim, L., Chang, S., Kim, W. S., Roh, M. S., Kim, T. J., *et al.* 2017. Molecular Testing of Lung Cancers. *Journal of pathology and translational medicine*, 51(3), 242-254.
- Siegel, R.L., Miller, K.D., Jemal, A. Cancer statistics, 2018. *CA Cancer J Clin.* Jan;68(1):7-30.
- Simmons, C.P., Koinis, F., Fallon, M.T., Fearon, K.C., Bowden, J., Solheim, T.S., *et al.* 2017. Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors. *Lung Cancer.* Jun;88(3):304-9.
- Sun, H.B., Ou, W., Li, Y., Fang, Q., Qin, J., Zhang, L., *et al.* 2013. Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy in Resected Advanced Non-Small-Cell Lung Cancer. *Clin Lung Cancer.* Jul;14(4):376-82.
- Supriadi, K. 2014. Angka Tahan Hidup Pasien Kanker Paru Kelompok Bukan Sel Kecil Non Skuamosa yang mendapat Terapi Target *Epidermal Growth Factor Receptor-Tyrosin Kinase Inhibitor* dan yang mendapat Kemoterapi Lini Pertama di RS Persahabatan. Diakses melalui <http://lib.ui.ac.id/file?file=digital/2016-5/20417087-SP-Kasum%20Supriadi.pdf> pada tanggal 8 Mei 2019.
- Sastroasmoro, S., Ismael, S. 2008. Dasar-Dasar Metodologi Penelitian Klinis. Jakarta: CV Sagung Seto.
- Tammemagi, C.M., Neslund-Dudas, C., Simoff, M., Kvale, P. 2003. Impact of comorbidity on lung cancer survival. *Int J Cancer.* Mar 1;103(6):792-802.
- Taniguchi, Y., Tamiya, A., Nakahama, K., Naoki, Y., Kanazu, M., Omachi, N., *et al.* 2017. Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors. *Oncology letters*, 14(6), 7589-7596.
- Tas, F., Ciftci, R., Kilic, L., Karabulut, S. 2013. *Age is a prognostic factor affecting survival in lung cancer patients.* *Oncol Lett* 6(5): 1507–1513.
- Torre, L.A. 2015. Global cancer statistics, 2012. *CA Cancer J Clin* 65(2):87 – 108.
- Travis, W.D., Brambilla, E., Muller-Hermelink, H.K., Harris, C.C. 2004. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; *World Health Organization Classification of Tumours*; vol 10

- Travis, W.D., Brambilla, E, Noguchi, M, Nicholson, A.G., Geisinger, K.R., Yatabe, Y, *et al.* 2011. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol.*;6(2):244–285.
- Tsai, Chang-Hung, Kung, Pei-Tseng, Kuo, Wei-Yin, Tsai, Wen-Chen. 2020. Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: a national cohort study in Taiwan. *BMJ Open*;10:e034351.
- Tseng, Chien-Hua, Chiang, Chun-Ju, Tseng, Jeng-Sen, Yang, Tsung-Ying, Hsu, Kuo-Hsuan, Chen, Kun-Chieh, *et al.* 2017. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. *Oncotarget* 8 (58): 98384-98393.
- Villa, C., Cagle, P. T., Johnson, M., Patel, J. D., Yeldandi, A. V., *et al.*, 2014. Correlation of EGFR Mutation Status With Predominant Histologic Subtype of Adenocarcinoma According to the New Lung Adenocarcinoma Classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. *Arch Pathol Lab Med*, 138:1353–1357.
- Visbal, A.L., Williams, B.A., Nichols, F.C. 3rd, Marks, R.S., Jett, J.R., Aubry, M.C., *et al.* 2004. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. *Ann Thorac Surg.* Jul;78(1):209-15; discussion 215.
- Wang, L., Correa, C. R., Hayman, J. A., Zhao, L., Cease, K., Brenner, D., *et al.* 2009. Time to Treatment in Patients With Stage III Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, 74(3), 790-795.
- Welsh, J. W., Komaki, R., Amini, A., Munsell, M. F., Unger, W., Allen, P. K., *et al.* 2013. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, 31(7), 895–902.
- Wu, Chia-Che, Rau, Kun-Ming, Lee, Wei-Chieh, Hsieh, Meng-Che, Liu, Jia-Sin, Chen, Yen-Yang, *et al.* 2019. Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study. *J. Clin. Med.* 8, 24.

Wu, K., House, L., Liu, W., Cho, W.C.S. 2012. Personalized Targeted Therapy for Lung Cancer. *Int. J. Mol. Sci.*, 13, 11471-11496.